ATE378056T1 - Medizinische verwendung von stammzellen, die vegfr-1 exprimieren - Google Patents

Medizinische verwendung von stammzellen, die vegfr-1 exprimieren

Info

Publication number
ATE378056T1
ATE378056T1 AT02752822T AT02752822T ATE378056T1 AT E378056 T1 ATE378056 T1 AT E378056T1 AT 02752822 T AT02752822 T AT 02752822T AT 02752822 T AT02752822 T AT 02752822T AT E378056 T1 ATE378056 T1 AT E378056T1
Authority
AT
Austria
Prior art keywords
stem cells
cells expressing
vegfr
directed
present
Prior art date
Application number
AT02752822T
Other languages
English (en)
Inventor
Shahin Rafii
Larry Witte
Original Assignee
Imclone Systems Inc
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Cornell Res Foundation Inc filed Critical Imclone Systems Inc
Application granted granted Critical
Publication of ATE378056T1 publication Critical patent/ATE378056T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
AT02752822T 2001-08-10 2002-08-12 Medizinische verwendung von stammzellen, die vegfr-1 exprimieren ATE378056T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31170501P 2001-08-10 2001-08-10

Publications (1)

Publication Number Publication Date
ATE378056T1 true ATE378056T1 (de) 2007-11-15

Family

ID=23208088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02752822T ATE378056T1 (de) 2001-08-10 2002-08-12 Medizinische verwendung von stammzellen, die vegfr-1 exprimieren

Country Status (9)

Country Link
US (1) US20050026220A1 (de)
EP (1) EP1423012B1 (de)
JP (1) JP2005526482A (de)
AT (1) ATE378056T1 (de)
AU (1) AU2002355580A1 (de)
CA (1) CA2454251A1 (de)
DE (1) DE60223556T2 (de)
ES (1) ES2299590T3 (de)
WO (1) WO2003014326A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288521B2 (en) * 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US7291597B2 (en) * 2000-04-06 2007-11-06 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US8173372B2 (en) * 2002-05-16 2012-05-08 Absorber Ab Methods of donor specific crossmatching
US20060104962A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US20060104963A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
WO2005113749A2 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Stem cell populations and methods of use
AU2005285246B2 (en) * 2004-09-03 2011-07-21 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
WO2007021210A1 (fr) * 2005-08-15 2007-02-22 Krasnozhenyuk Alexei Dmitrievi Methode de traitement de maladies causees par une pathologie vasculaire
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
GB0818725D0 (en) 2008-10-13 2008-11-19 Habib Nagy A Pharmaceutical composition

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
SK281143B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5543503A (en) * 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
JP3658471B2 (ja) * 1996-09-30 2005-06-08 株式会社日立製作所 電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム
DE69736222T2 (de) * 1996-11-21 2007-05-24 Kyowa Hakko Kogyo K.K. Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2000079275A1 (en) * 1999-06-17 2000-12-28 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for diseases with participation of macrocytes/macrophages
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
ATE526981T1 (de) * 2000-04-12 2011-10-15 Vib Vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
AU2001264946A1 (en) * 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
CA2450954A1 (en) * 2001-06-20 2003-01-03 Imclone Systems Incorporated Method of treating atherosclerosis and other inflammatory diseases
US20040242851A1 (en) * 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
EP1416960A4 (de) * 2001-07-13 2006-02-22 Imclone Systems Inc Vegfr-1-antikörper zur behandlung von brustkrebs
EP1682103A1 (de) * 2003-10-27 2006-07-26 Novartis AG Indolyl-pyrroldion-derivate zur behandlung von neurologischen und vaskulären störungen im zusammenhang mit der beta-amyloid-erzeugung und/oder aggregation
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors

Also Published As

Publication number Publication date
CA2454251A1 (en) 2003-02-20
EP1423012B1 (de) 2007-11-14
US20050026220A1 (en) 2005-02-03
ES2299590T3 (es) 2008-06-01
WO2003014326A3 (en) 2003-04-10
DE60223556D1 (de) 2007-12-27
EP1423012A4 (de) 2005-01-05
DE60223556T2 (de) 2008-09-18
WO2003014326A2 (en) 2003-02-20
AU2002355580A1 (en) 2003-02-24
EP1423012A2 (de) 2004-06-02
JP2005526482A (ja) 2005-09-08

Similar Documents

Publication Publication Date Title
DE60223556D1 (de) Medizinische verwendung von stammzellen, die vegfr-1 exprimieren
ATE392481T1 (de) Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DE69829412D1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
DE60142508D1 (de) Menschliche aminoacyl-trna synthetase polypeptide zur regulation der angiogenese
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE323692T1 (de) Piperidinylsubstituierte pyridylalkan-, -alken- und -alkincarbonsäuren als cytostatika und immunsuppressiva
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
MXPA02008239A (es) Gen humano de la esquizofrenia.
ATE257485T1 (de) Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung
EP1141286A4 (de) Cytokinrezeptor-kette
ATE269340T1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
DE69534597D1 (de) Melatoninrezeptoren mit hoher affinität und ihre verwendungen
ATE415961T1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7- dimethylbicycloä2.2.1ühept-1- ylmethanesulphonamide-familie
ATE557092T1 (de) Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
NO20051967L (no) 3,4-disubstituerte pyroler og deres anvendelse ved behandling av inflammatoriske sykdommer.
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
DE60042793D1 (de) Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
DE602004001509D1 (de) Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
ATE407217T1 (de) Hochexpression und herstellung von recombinanter s-adenosyl homocysteinase mit hochspezifischer aktivität und verbesserte testverfahren für s- adenosylmethionine (sam)
ATE325816T1 (de) Regulatorische regionen des gens für den melatonin 1a rezeptor und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties